Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long^*, Robyn P. M. Saw, Serigne Lo, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, Jenny H. Lee, Hansol Lee, Peter M. Ferguson, Robert V. Rawson, James S. Wilmott, John F. Thompson, Richard F. Kefford, Sydney Ch'ng, Jonathan R. Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J. SpillaneRichard A. Scolyer, Alexander M. Menzies

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

134 Citations (Scopus)

1 results

Active

Molecular determinants of risk, progression and treatment response in melanoma
Kefford, R., Thompson, J., Hersey, P., Mann, G., Scolyer, R., Hayward, N. & Long, G.
1/01/16 → …
Project: Research

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Projects

Search results

Molecular determinants of risk, progression and treatment response in melanoma

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial